Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy May Be Hit With Significant Disgorgement Penalty For GMP Violations

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Ranbaxy's long-running encounter with U.S. FDA over American regulatory allegations of significant deficiencies at two Ranbaxy manufacturing sites - Paonta Sahib and Dewas - may be headed for a settlement in coming months, with the Indian generics flag-bearer paying out several million dollars in penalties
Advertisement

Related Content

Is Ranbaxy Inching Closer To Resolution Of Its GMP Disputes With U.S. FDA?
Ranbaxy Set To launch Aricept Generic In U.S. As FDA OKs Ohm Labs Data; Will Lipitor Be Next ?
As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?
As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?
Daiichi Sankyo Rolls Out Generics In Japan While Ranbaxy Products Still On Hold In U.S.
Jordan's Hikma Sees Double-digit Sales Growth In First Half, Continues Aggressive M&A Expansion In Middle East
Ranbaxy Shuffles Its CEO Again, Atul Sobti Steps Down As Daiichi Sankyo Appoints New Leader
Corrective Actions "Inadequate," U.S. FDA Warns Ranbaxy; Threatens Seizure And Injunction
Ranbaxy Woes Continue With 30-plus Product Import Alert
Ranbaxy Woes Continue With 30-plus Product Import Alert
Advertisement
UsernamePublicRestriction

Register

SC075769

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel